ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug, or RLD, Alinia. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1M, based on December 2024 moving annual total IQVIA data.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals announces royalty obligation buyout for Iluvien, Yutiq
- Positive Outlook for ANI Pharmaceuticals: FDA Approval and Strategic Moves Drive Buy Rating
- ANI Pharmaceuticals announces FDA approval for expansion of Iluvien label
- ANI Pharmaceuticals initiated with a Buy at Jefferies
- ANI Pharmaceuticals initiated with an Overweight at JPMorgan